GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Gross Margin %

AVBP (ArriVent BioPharma) Gross Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. ArriVent BioPharma's Gross Profit for the three months ended in Sep. 2024 was $0.00 Mil. ArriVent BioPharma's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, ArriVent BioPharma's Gross Margin % for the quarter that ended in Sep. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for ArriVent BioPharma's Gross Margin % or its related term are showing as below:


AVBP's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.58
* Ranked among companies with meaningful Gross Margin % only.

ArriVent BioPharma had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for ArriVent BioPharma was 0.00% per year.


ArriVent BioPharma Gross Margin % Historical Data

The historical data trend for ArriVent BioPharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Gross Margin % Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23
Gross Margin %
- - -

ArriVent BioPharma Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ArriVent BioPharma's Gross Margin %

For the Biotechnology subindustry, ArriVent BioPharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ArriVent BioPharma's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's Gross Margin % falls into.



ArriVent BioPharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

ArriVent BioPharma's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

ArriVent BioPharma's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


ArriVent BioPharma  (NAS:AVBP) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

ArriVent BioPharma had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


ArriVent BioPharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ArriVent BioPharma Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.